Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 13,122,800 | 12,853,460 | 12,516,280 | 11,311,000 | 10,229,420 |
| Cost of Goods | 4,951,242 | 4,981,741 | 3,983,642 | 3,569,981 | 3,419,920 |
| Gross Profit | 8,171,562 | 7,871,726 | 8,532,633 | 7,741,017 | 6,809,502 |
| Operating Expenses | 4,413,423 | 6,693,740 | 5,860,967 | 5,400,683 | 4,475,774 |
| Operating Income | 3,758,382 | 1,178,725 | 2,672,308 | 2,341,315 | 2,334,647 |
| Interest Expense | 284,462 | 256,742 | 275,780 | 268,378 | 277,179 |
| Other Income | 12,076 | 2,906 | 13,789 | -18,171 | 35,854 |
| Pre-tax Income | 3,485,996 | 924,889 | 2,410,317 | 2,054,766 | 2,093,322 |
| Income Tax | 578,316 | -308,929 | 523,982 | -95,050 | 355,782 |
| Net Income Continuous | 2,907,681 | 1,233,818 | 1,886,335 | 2,149,816 | 1,737,540 |
| Minority Interests | 489,757 | 244,158 | 275,780 | 199,885 | 257,873 |
| Net Income | $2,417,924 | $989,660 | $1,610,555 | $1,949,931 | $1,479,667 |
| EPS Basic Total Ops | 1.20 | 0.49 | 0.80 | 0.98 | 0.74 |
| EPS Basic Continuous Ops | 1.45 | 0.61 | 0.94 | 1.07 | 0.87 |
| EPS Diluted Total Ops | 1.20 | 0.51 | 0.80 | 0.98 | 0.73 |
| EPS Diluted Continuous Ops | 1.45 | 0.64 | 0.93 | 1.06 | 0.87 |
| EBITDA(a) | $4,703,008 | $1,178,722 | $4,012,532 | $3,276,241 | $2,832,467 |